vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Hippo Holdings Inc. (HIPO). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $120.4M, roughly 1.5× Hippo Holdings Inc.). Hippo Holdings Inc. runs the higher net margin — 5.0% vs -0.7%, a 5.7% gap on every dollar of revenue. On growth, Hippo Holdings Inc. posted the faster year-over-year revenue change (18.2% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $9.1M). Over the past eight quarters, Hippo Holdings Inc.'s revenue compounded faster (18.9% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.
AVNS vs HIPO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $120.4M |
| Net Profit | $-1.3M | $6.0M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | 5.6% |
| Net Margin | -0.7% | 5.0% |
| Revenue YoY | 0.7% | 18.2% |
| Net Profit YoY | 99.7% | -86.4% |
| EPS (diluted) | $-0.02 | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $120.4M | ||
| Q3 25 | $177.8M | $120.6M | ||
| Q2 25 | $175.0M | $117.3M | ||
| Q1 25 | $167.5M | $110.3M | ||
| Q4 24 | $179.6M | $101.9M | ||
| Q3 24 | $170.4M | $95.5M | ||
| Q2 24 | $171.7M | $89.6M | ||
| Q1 24 | $166.1M | $85.1M |
| Q4 25 | $-1.3M | $6.0M | ||
| Q3 25 | $-1.4M | $98.1M | ||
| Q2 25 | $-76.8M | $1.3M | ||
| Q1 25 | $6.6M | $-47.7M | ||
| Q4 24 | $-397.3M | $44.2M | ||
| Q3 24 | $4.3M | $-8.5M | ||
| Q2 24 | $1.8M | $-40.5M | ||
| Q1 24 | $-900.0K | $-35.7M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | 5.6% | ||
| Q3 25 | 0.1% | 81.3% | ||
| Q2 25 | -42.6% | 3.4% | ||
| Q1 25 | 6.1% | -41.3% | ||
| Q4 24 | -233.0% | 46.3% | ||
| Q3 24 | 7.0% | -5.4% | ||
| Q2 24 | 3.7% | -40.7% | ||
| Q1 24 | 2.4% | -38.7% |
| Q4 25 | -0.7% | 5.0% | ||
| Q3 25 | -0.8% | 81.3% | ||
| Q2 25 | -43.9% | 1.1% | ||
| Q1 25 | 3.9% | -43.2% | ||
| Q4 24 | -221.2% | 43.4% | ||
| Q3 24 | 2.5% | -8.9% | ||
| Q2 24 | 1.0% | -45.2% | ||
| Q1 24 | -0.5% | -42.0% |
| Q4 25 | $-0.02 | $0.31 | ||
| Q3 25 | $-0.03 | $3.77 | ||
| Q2 25 | $-1.66 | $0.05 | ||
| Q1 25 | $0.14 | $-1.91 | ||
| Q4 24 | $-8.64 | $1.81 | ||
| Q3 24 | $0.09 | $-0.34 | ||
| Q2 24 | $0.04 | $-1.64 | ||
| Q1 24 | $-0.02 | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $218.3M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $436.1M |
| Total Assets | $1.1B | $1.9B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $218.3M | ||
| Q3 25 | $70.5M | $247.7M | ||
| Q2 25 | $90.3M | $198.9M | ||
| Q1 25 | $97.0M | $140.9M | ||
| Q4 24 | $107.7M | $197.6M | ||
| Q3 24 | $89.0M | $191.2M | ||
| Q2 24 | $92.2M | $175.9M | ||
| Q1 24 | $75.8M | $223.4M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $436.1M | ||
| Q3 25 | $778.0M | $421.5M | ||
| Q2 25 | $776.3M | $332.5M | ||
| Q1 25 | $839.4M | $322.8M | ||
| Q4 24 | $828.5M | $362.1M | ||
| Q3 24 | $1.2B | $326.4M | ||
| Q2 24 | $1.2B | $322.6M | ||
| Q1 24 | $1.2B | $351.2M |
| Q4 25 | $1.1B | $1.9B | ||
| Q3 25 | $1.1B | $1.9B | ||
| Q2 25 | $1.0B | $1.7B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $1.7B | $1.5B | ||
| Q2 24 | $1.7B | $1.5B | ||
| Q1 24 | $1.7B | $1.5B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $9.2M |
| Free Cash FlowOCF − Capex | $21.3M | $9.1M |
| FCF MarginFCF / Revenue | 11.8% | 7.6% |
| Capex IntensityCapex / Revenue | 3.8% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.53× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $14.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $9.2M | ||
| Q3 25 | $14.0M | $16.9M | ||
| Q2 25 | $6.8M | $24.7M | ||
| Q1 25 | $25.7M | $-35.6M | ||
| Q4 24 | $57.9M | $47.5M | ||
| Q3 24 | $23.0M | $46.8M | ||
| Q2 24 | $27.8M | $-10.6M | ||
| Q1 24 | $-8.0M | $17.7M |
| Q4 25 | $21.3M | $9.1M | ||
| Q3 25 | $7.0M | $16.8M | ||
| Q2 25 | $-4.2M | $24.6M | ||
| Q1 25 | $19.0M | $-35.7M | ||
| Q4 24 | $53.1M | $47.2M | ||
| Q3 24 | $20.0M | — | ||
| Q2 24 | $21.9M | $-10.7M | ||
| Q1 24 | $-12.1M | $17.6M |
| Q4 25 | 11.8% | 7.6% | ||
| Q3 25 | 3.9% | 13.9% | ||
| Q2 25 | -2.4% | 21.0% | ||
| Q1 25 | 11.3% | -32.4% | ||
| Q4 24 | 29.6% | 46.3% | ||
| Q3 24 | 11.7% | — | ||
| Q2 24 | 12.8% | -11.9% | ||
| Q1 24 | -7.3% | 20.7% |
| Q4 25 | 3.8% | 0.1% | ||
| Q3 25 | 3.9% | 0.1% | ||
| Q2 25 | 6.3% | 0.1% | ||
| Q1 25 | 4.0% | 0.1% | ||
| Q4 24 | 2.7% | 0.3% | ||
| Q3 24 | 1.8% | 0.0% | ||
| Q2 24 | 3.4% | 0.1% | ||
| Q1 24 | 2.5% | 0.1% |
| Q4 25 | — | 1.53× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | 19.00× | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
HIPO
Segment breakdown not available.
